Susanne Rasoul‐Rockenschaub

Medical University of Vienna

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Gabriela Berlakovich

Medical University of Vienna

Thomas Soliman

Medical University of Vienna

Markus Peck‐Radosavljevic

Klinikum Klagenfurt

Ferdinand Mühlbacher

Medical University of Vienna

Martin Bodingbauer

Unfallkrankenhaus Meidling

Gerd R. Silberhumer

Medical University of Vienna

Rudolf Steininger

Medical University of Vienna

H. Pokorny

Kaiser-Franz-Josef-Spital

Michael Trauner

Medical University of Vienna

Wolfgang Sieghart

Medical University of Vienna

Cooperative Institutions

Medical University of Vienna

232

University of Vienna

131

Vienna General Hospital

128

Universitätsklinik für Chirurgie Wien

Universitätszahnklinik Wien

Comprehensive Cancer Center Vienna

Universität Innsbruck

Innsbruck Medical University

Wilhelminen Hospital

Statistics Austria

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression

Transplant International (2004)

R. Roka Susanne Rasoul‐Rockenschaub J. Róka Reinhard Kirnbauer Ferdinand M�hlbacher

Immunosuppression

10.1007/s00147-004-0738-z

Cite

Citations (52)

Outcome of patients with Child-Pugh C liver cirrhosis and hepatocellular carcinoma after liver transplantation

Zeitschrift für Gastroenterologie (2011)

Wolfgang Sieghart Matthias Pinter I Graziadei Florian Hucke Susanne Rasoul‐Rockenschaub

Background: Here, we provide the first systematic outcome analysis of Child Pugh C (CPC) patients transplanted for HCC.

10.1055/s-0031-1279847

Cite

Citations (0)

Wartelistenmortalität und Post-Transplant-Überleben in PatientInnen mit Cholestatischer Lebererkrankung – 24-Jahre Zentrumspraxis

Zeitschrift für Gastroenterologie (2017)

Katharina Staufer Susanne Rasoul‐Rockenschaub Th. Soliman Gabriela Berlakovich

Die Lebertransplantation (LT) ist eine etablierte Methode zur Behandlung von cholestatischen Lebererkrankungen im Endstadium. Diese Studie untersuchte die Wartelistenmortalität, sowie das post-LT-Überleben in PatientInnen mit Primär Biliärer (PBC), bzw. Primär Sklerosierender Cholangitis (PSC) vor und nach Einführung des Model of End-Stage Liver Disease (MELD)-Scores an der Medizinischen Universität Wien.

10.1055/s-0037-1603434

Cite

Citations (0)

Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: Immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination

Vaccine (2011)

Heimo Lagler J. M. Wenisch Selma Tobudic Guido A. Gualdoni S Rödler

Seroconversion

ELISPOT

Hemagglutination assay

Inactivated vaccine

10.1016/j.vaccine.2011.07.050

Cite

Citations (19)

Good outcome after liver transplantation for ALD without a 6 months abstinence rule prior to transplantation including post-transplant CDT monitoring for alcohol relapse assessment - a retrospective study

Transplant International (2016)

Dagmar Kollmann Susanne Rasoul‐Rockenschaub Irene Steiner Edith Freundorfer Georg Györi

Carbohydrate deficient transferrin

Liver disease

10.1111/tri.12756

Cite

Citations (32)

Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection

Nephrology Dialysis Transplantation (2016)

Elisabeth Schwaiger Farsad Eskandary Nicolas Kozakowski Gregor Bond Željko Kikić

Apheresis-based desensitization allows for successful transplantation across major immunological barriers. For donor-specific antibody (DSA)- and/or crossmatch-positive transplantation, however, it has been shown that even intense immunomodulation may not completely prevent antibody-mediated rejection (ABMR).In this study, we evaluated transplant outcomes in 101 DSA+ deceased donor kidney transplant recipients (transplantation between 2009 and 2013; median follow-up: 24 months) who were subjected to immunoadsorption (IA)-based desensitization. Treatment included a single pre-transplant IA session, followed by anti-lymphocyte antibody and serial post-transplant IA. In 27 cases, a positive complement-dependent cytotoxicity crossmatch (CDCXM) was rendered negative immediately before transplantation. Seventy-four of the DSA+ recipients had a negative CDCXM already before IA.Three-year death-censored graft survival in DSA+ patients was significantly worse than in 513 DSA- recipients transplanted during the same period (79 versus 88%, P = 0.008). Thirty-three DSA+ recipients (33%) had ABMR. While a positive baseline CDCXM showed only a trend towards higher ABMR rates (41 versus 30% in CDCXM- recipients, P = 0.2), DSA mean fluorescence intensity (MFI) in single bead assays significantly associated with rejection, showing 20 versus 71% ABMR rates at <5000 versus >15 000 peak DSA MFI. The predictive value of MFI was moderate, with the highest accuracy at a median of 13 300 MFI (after cross-validation: 0.72). Other baseline variables, including CDC assay results, human leukocyte antigen mismatch, prior transplantation or type of induction treatment, did not add independent predictive information.IA-based desensitization failed to prevent ABMR in a considerable number of DSA+ recipients. Assessing DSA MFI may help stratify risk of rejection, supporting its use as a guide to organ allocation and individualized treatment.

Donor-Specific Antibodies

Isoantibodies

10.1093/ndt/gfw027

Cite

Citations (64)

Early basal insulin therapy decreases new-onset diabetes after renal transplantation

Diabetes Technology & Therapeutics (2013)

Manfred Hecking Michael Haidinger Dominik Döller Johannes Werzowa Andrea Tura

No effective interventions to reduce risk for new-onset diabetes after transplantation (NODAT), a condition associated with postoperative hyperglycemia and reduced patient and graft survival, have been established. In this 1-year, proof-of-concept clinical trial, we randomly assigned 50 renal transplant recipients to immediate-postoperative isophane insulin for evening blood glucose ≥140 mg/dl (treatment group) or short-acting insulin and/or oral antidiabetic agents for blood glucose ≥180-250 mg/dl (standard-of-care control group). We included only patients without a history of diabetes who received tacrolimus. By the third postoperative evening, all patients in the treatment group had blood glucose ≥140 mg/dl and were subsequently treated with basal insulin; during the first 3 weeks after transplantation, the mean ± SD daily insulin dosage was 17±11 IU/d. Among controls, 23 (92%) of 25 had blood glucose ≥200 mg/dl and 18 (72%) of 25 received standard-of-care antihyperglycemic treatment. Asymptomatic hypoglycemia occurred five times in the treatment group and once in the control group. Throughout follow-up, the treatment group had 73% lower odds of NODAT (odds ratio, 0.27) than the control group, and hemoglobin A1c was on average 0.38% lower in the treatment group than the control group. Twelve months after transplantation, all patients in the treatment group were insulin-independent, whereas 7 (28%) of 25 controls required antidiabetic agents. The groups did not differ for insulin sensitivity, but the treatment group showed better β-cell function throughout the 1-year follow-up. In conclusion, this study suggests regimens that include basal insulin significantly reduce the odds for NODAT after renal transplantation, presumably via insulin-mediated protection of β cells.

Source

Cite

Citations (0)

NASH cirrhosis as an increasing cause for liver transplantation – the Viennese experience

Zeitschrift für Gastroenterologie (2016)

LW Unger Merima Herac Thomas Reiberger KA Staufer Andreas Salat

Background: Non-alcoholic steatohepatitis (NASH) represents the hepatic manifestation of the metabolic syndrome and can ultimately lead to liver cirrhosis. Since the global prevalence of the metabolic syndrome is increasing, NASH cirrhosis has become a leading cause for orthotopic liver transplantation (OLT). NASH recurrence may be observed after transplantation, not only due to host factors but also due to immunosuppressive therapy's side-effects. Some cases of NASH might have been misclassified as cryptogenic cirrhosis (CC) in the past, while the awareness for NASH cirrhosis has increased in recent years. Here we aimed to evaluate explant histology and the clinical course after OLT for CC versus NASH cirrhosis.

Steatohepatitis

Nonalcoholic steatohepatitis

10.1055/s-0036-1583988

Cite

Citations (0)

High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey

Nephrology Dialysis Transplantation (2016)

Volker Aßfalg Norbert Hüser Marieke van Meel Bernhard Haller Axel Rahmel

BackgroundIn the Eurotransplant Kidney Allocation System (ETKAS), transplant candidates can be considered for high-urgency (HU) status in case of life-threatening inability to undergo renal replacement therapy. Data on the outcomes of HU transplantation are sparse and the benefit is controversial.

Economic shortage

Renal replacement therapy

10.1093/ndt/gfv446

Cite

Citations (14)

Hypothyroidism and Hyponatremia: Rather Coincidence Than Causality

Thyroid (2017)

Peter Wolf Hannes Beiglböck Sabina Smaijs Thomas Wrba Susanne Rasoul‐Rockenschaub

Background: Hypothyroidism is referred to be a rare but possible cause of hyponatremia. However, there is only poor evidence supporting this association. Since hyponatremia and hypothyroidism are both common conditions themselves, co-occurrence does not have to be causal. Methods: To address a potential relationship, a retrospective analysis of data from the Division of Endocrinology of the Medical University of Vienna from April 2004 to February 2016 was performed. A total of 8053 hypothyroid patients (48 ± 18 years of age; 71% female) with thyrotropin >4.0 μIU/mL and available blood tests for free thyroxine and sodium (Na+) within maximal ± seven days were included and screened for hyponatremia. Patients' records were searched for concomitant disease and medication when Na+ concentration was <135 mmol/L. Results: Hyponatremia was present in 448/8053 (5.56%) patients. Analysis of medical history revealed potential alternative causes of hyponatremia in 442/448 (98.88%) patients (i.e., side effects of medication, concomitant underlying disease, or other endocrine disorders). This distribution did not differ between patients suffering from clinical or subclinical hypothyroidism. No case of clinically relevant hyponatremia (Na+ < 130 mmol/L), present in 111/448 (24.78%) patients could be attributed only to hypothyroidism. There was a very weak but statistically significant trend toward a positive association between thyroid function and serum Na+ levels (Na+/thyrotropin: R = 0.022, p = 0.046; Na+/free thyroxine: R = −0.047, p < 0.001). Conclusion: The results suggest that hypothyroid patients with moderate to severe hyponatremia often have other potential explanations for their low serum Na+ concentrations in routine care.

Concomitant

Subclinical infection

Thyroid disease

10.1089/thy.2016.0597

Cite

Citations (20)